Nonalcoholic Steatohepatitis

Adam Sheka; Oyedele Adeyi; Julie Thompson; Bilal Hameed; Peter A. Crawford; Sayeed Ikramuddin

doi:10.1001/jama.2020.2298

Abstract

Nonalcoholic steatohepatitis affects 3% to 6% of the US population, is more prevalent in patients with metabolic disease and obesity, progresses to cirrhosis in approximately 20% of cases, and is associated with increased rates of liver-specific and overall mortality. Early identification and targeted treatment of patients with nonalcoholic steatohepatitis are needed to improve patient outcomes, including directing patients toward intensive lifestyle modification to promote weight loss and referral for bariatric surgery as indicated for management of obesity and metabolic disease.

Keywords

MedicineNonalcoholic fatty liver diseaseCirrhosisSteatohepatitisLiver biopsyMetabolic syndromePopulationWeight lossDyslipidemiaFatty liverInternal medicineNonalcoholic steatohepatitisType 2 diabetesLiver diseaseGastroenterologyObesityDiabetes mellitusDiseaseBiopsyEndocrinologyEnvironmental health

Affiliated Institutions

Related Publications

Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome

Giulio Marchesini , Elisabetta Bugianesi , Gabriele Forlani +8 more

Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin–resistance syndrome, at present defined as the metabolic syndrome, whose limits were recently set. ...

2003 Hepatology 2654 citations

Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments

Akira Sasaki , Hiroyuki Nitta , Koki Otsuka +4 more

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly common cause of chronic liver disease worldwide. The diagnosis of NASH is cha...

2014 Frontiers in Endocrinology 128 citations

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Gregory C. Vernon , Ancha Baranova , Zobair M. Younossi

Aliment Pharmacol Ther 2011; 34: 274–285 Summary Background Non‐alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence co...

2011 Alimentary Pharmacology & Therapeutics 3042 citations

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Hannah Woopen , Stephen A. Harrison

Nonalcoholic fatty liver disease (NAFLD) is now the most common form of liver disease in developed countries, with an estimated prevalence of 20%‐30% and increasing to as high a...

2016 Hepatology 69 citations

Non-alcoholic fatty liver disease

Elizabeth E. Powell , Vincent Wai‐Sun Wong , Mary E. Rinella

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum ...

2021 The Lancet 2416 citations

Publication Info

Year: 2020
Type: review
Volume: 323
Issue: 12
Pages: 1175-1175
Citations: 1290
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Nonalcoholic Steatohepatitis

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1290

OpenAlex

Cite This

APA Style

                            
                                
                                    Adam Sheka, 
                                
                                    Oyedele Adeyi, 
                                
                                    Julie Thompson
                                
                                et al.
                            
                            (2020). 
                            Nonalcoholic Steatohepatitis. 
                            JAMA
                            , 323
                            (12)
                            , 1175-1175.
                            https://doi.org/10.1001/jama.2020.2298
                        

Identifiers

DOI: 10.1001/jama.2020.2298